PEPFAR reauthorization legislation should make HIV/AIDS treatment 'priority,' letter to editor says

NewsGuard 100/100 Score

"When it comes to AIDS, treatment is prevention," Republican Sens. Richard Burr (N.C.) and Tom Coburn (Okla.) write in a Washington Post letter to the editor in response to a recent opinion piece by columnist Michael Gerson.

According to Burr and Coburn, Gerson in the opinion piece "baselessly attacked [their] position on the President's Emergency Plan for AIDS Relief" and "went so far as to accuse [them] of being 'indifferent to human suffering.'" They add, "Nothing could be further from the truth." The authors write that along with Sen. Jon Kyl (R-Ariz.), they have introduced "legislation that would continue PEPFAR's lifesaving focus by maintaining the mandate that at least 55% of all funding through the program be tied to treatment" for HIV-positive people.

"If we fail to aggressively treat patients, we endorse the spread of the virus," Burr and Coburn write, adding, "By requiring that the majority of PEPFAR funds go toward treatment, we are working to prevent the spread of this devastating virus."

HIV/AIDS has "destroyed far too many lives already, and it is time to say enough is enough," the authors write, concluding, "We must continue to support legislation that makes treatment a funding priority" (Burr/Coburn, Washington Post, 5/20).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unveiling the key role of RNA modification in HIV-1 survival and replication